BURLINGTON, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as the licensing and acquisition of, and investment in, development stage compounds, biologics and companies, today announced the U.S. Patent and Trademark Office (USPTO) has granted a second key patent for CNDO-109 directed to the activated Natural Killer (NK) cell compositions employed in its NK cell therapy program, and has further issued a Notice of Allowance in an additional pending application directed to pharmaceutical compositions comprising these activated NK cells. The activated NK cells are prepared by a patented process licensed by Coronado from UCL Business PLC, which is already the subject of a previously-granted U.S. patent. Similar patent protection has been obtained in Australia and India and applications are still pending in Europe, Japan and Canada.
Help employers find you! Check out all the jobs and post your resume.
